Anemia Drugs Market Report 2026

Anemia Drugs Market Overview

• Anemia Drugs market size has reached to $15.77 billion in 2025 • Expected to grow to $22.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Rising Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomic Sequencing And Demand For Tailored Therapies • Market Trend: Technological Advancements Enhancing Red Blood Cell Production And Iron Metabolism • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anemia Drugs Market?

Anemia drugs are medications that treat low red blood cell (RBC) levels or hemoglobin in the blood. These drugs improve oxygen delivery in the body and reduce fatigue, treating the underlying cause of anemia, such as iron deficiency, chronic disease, or kidney disorders. The main drugs types of anemia drugs are dietary supplements, and medicines. Dietary supplements refer to products taken orally that contain essential nutrients such as iron, folic acid, or vitamin B12 to help manage or prevent anemia. The various therapy types include oral iron therapy, parenteral iron therapy, red blood cell transfusion, and other supportive treatments. The various anemia types are iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and other anemia types. These are distributed through various channels, including hospital pharmacies, online pharmacies, and pharmacies. The different end-users include clinics, healthcare facilities, and home healthcare.

What Is The Anemia Drugs Market Growth Forecast?

The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $22.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to aging population growth, chronic disease anemia management, injectable iron adoption, home healthcare expansion, preventive supplementation. Major trends in the forecast period include rising use of erythropoiesis-stimulating agents, growth of intravenous iron therapy, expansion of home-based anemia management, increased focus on chronic disease anemia, shift toward combination supplement therapy.

Global Anemia Drugs Market Segmentation

1) By Drug Type: Dietary Supplements, Medicines 2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types 3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Other Anemia Types 4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 5) By End-User: Clinic, Healthcare, Home Healthcare Subsegments: 1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements 2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents

What Is The Driver Of The Anemia Drugs Market?

The increasing focus on personalized medicine is expected to propel the growth of the anemia drugs market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to an individual’s genetic makeup, lifestyle, and environment. The rising focus on personalized medicine is due to advancements in genomic sequencing, which allow for more precise identification of individual genetic variations linked to disease and treatment response. Personalized medicine supports anemia drug production by enabling tailored treatments based on individual genetic profiles, improving drug efficacy, and minimizing adverse effects for better patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant increase from 6 in 2022. Therefore, the increasing focus on personalized medicine drives the growth of the anemia drugs industry.

Key Players In The Global Anemia Drugs Market

Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, BioLineRx Ltd., Bluebird Bio Inc.

Global Anemia Drugs Market Trends and Insights

Major companies operating in the anemia drugs market are focusing on innovative drug developments, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), to improve iron metabolism and enhance red blood cell production for more effective anemia treatments. Oral HIF-PHI (Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors) are a class of oral medications that target and inhibit prolyl hydroxylase enzymes, which play a role in regulating the hypoxia-inducible factor (HIF) pathway. For instance, in February 2023, GSK plc, a UK-based pharmaceutical company, launched Jesduvroq, a treatment designed to improve red blood cell production and address anemia in adult patients with chronic kidney disease. This innovative anemia drug system features enhanced iron metabolism, improved red blood cell production, and personalized therapies. Jesduvroq is highly effective, boosting red blood cell production and addressing anemia in chronic kidney disease patients by enhancing iron metabolism for better treatment outcomes.

What Are Latest Mergers And Acquisitions In The Anemia Drugs Market?

In May 2023, Akebia Therapeutics, a US-based biopharmaceutical company, partnered with Medice Arzneimittel Pütter gmbh & Co. KG to commercialize Vafseo for anemia in Europe and Australia. Through this partnership, Akebia Therapeutics and Medice Arzneimittel Pütter aim to drive sustainable growth and enhance the availability of Vafseo for anemia treatment through increased accessibility and innovation. Medice Arzneimittel Pütter gmbh & Co. KG is a Germany-based pharmaceutical company specializing in anemia treatments and prescription medicines.

Regional Insights

North America was the largest region in the anemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anemia Drugs Market?

The anemia drugs market consists of sales of androgens, hydroxyurea, luspatercept and sotatercept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anemia Drugs Market Report 2026?

The anemia drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anemia drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.